AF9 antibody (N-Term)
-
- Target See all AF9 (MLLT3) Antibodies
- AF9 (MLLT3) (Protein AF-9 (MLLT3))
-
Binding Specificity
- AA 39-65, N-Term
-
Reactivity
- Human
-
Host
- Rabbit
-
Clonality
- Polyclonal
-
Conjugate
- This AF9 antibody is un-conjugated
-
Application
- Western Blotting (WB)
- Predicted Reactivity
- M
- Purification
- This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
- Immunogen
- This MLLT3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 39-65 amino acids from the N-terminal region of human MLLT3.
- Clone
- RB6802
- Isotype
- Ig Fraction
- Top Product
- Discover our top product MLLT3 Primary Antibody
-
-
- Application Notes
- WB: 1:1000
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C,-20 °C
- Storage Comment
- Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
- Expiry Date
- 6 months
-
- Target
- AF9 (MLLT3) (Protein AF-9 (MLLT3))
- Alternative Name
- MLLT3 (MLLT3 Products)
- Synonyms
- fc39c11 antibody, wu:fc39c11 antibody, zgc:110210 antibody, AF9 antibody, YEATS3 antibody, 2210011H10Rik antibody, 2610012I03Rik antibody, 3830408D16Rik antibody, Af9 antibody, D4Ertd321e antibody, Af-9 antibody, MLLT3, super elongation complex subunit antibody, myeloid/lymphoid or mixed-lineage leukemia; translocated to, 3 antibody, mllt3 antibody, MLLT3 antibody, Mllt3 antibody
- Background
- The human AF9 gene is one of the most common fusion partner genes with the ALL1 gene at 11q23 (also called MLL), resulting in the t(9,11)(p22,q23). The AF9 gene is more than 100 kb, and 2 patient breakpoint cluster regions (BCRs) have been identified, BCR1 is within intron 4, previously called site A, whereas BCR2 or site B spans introns 7 and 8. Several different structural elements have been identified in AF9, including a colocalizing in vivo DNA topo II cleavage site and an in vitro DNase I hypersensitive (DNase 1 HS) site in intron 7 in BCR2. Reversibility experiments demonstrated a religation of the topo II cleavage sites. In addition, 2 scaffold associated regions (SARs) are located centromeric to the topo II and DNase I HS cleavage sites and border breakpoint regions in 2 leukemic cells lines: SAR1 is located in intron 4, whereas SAR2 encompasses parts of exons 5-7. The patient breakpoint regions of AF9 share the same structural elements as the MLL BCR. A DNA breakage and repair model for nonhomologous recombination between MLL and its partner genes, particularly AF9, has been proposed.
- Molecular Weight
- 63351
- Gene ID
- 4300
- NCBI Accession
- NP_004520
- UniProt
- P42568
-